<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699110</url>
  </required_header>
  <id_info>
    <org_study_id>ERC-76/2020</org_study_id>
    <nct_id>NCT04699110</nct_id>
  </id_info>
  <brief_title>Adrenaline for the Treatment of No-Reflow in Normotensive Patients</brief_title>
  <official_title>Efficacy of Intracoronary Adrenaline and Its Comparison With Intracoronary Adenosine in the Treatment of No-Reflow in Normotensive Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Cardiovascular Diseases, Karachi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Cardiovascular Diseases, Karachi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      No-reflow is defined as the lack of myocardial perfusion despite opening of the epicardial&#xD;
      coronary vessels in the setting of percutaneous coronary intervention (PCI). It has been&#xD;
      demonstrated that either impaired flow or the absence of flow is associated with an increased&#xD;
      rate of mortality. Among available treatment options, intracoronary adenosine is widely used&#xD;
      in clinical practice, moreover, adrenaline is a safe alternative for the cases where use of&#xD;
      adenosine is limited due to presence of hypotension or bradycardia. Nonetheless, evidence&#xD;
      from retrospective and observational studies suggest that intracoronary adrenaline is well&#xD;
      tolerated and may exert encouraging effects in prompt recovery of flow in these patients.&#xD;
      However, very limited data are available on efficacy of intracoronary (IC) adrenaline in&#xD;
      normotensive patients. Therefore, this study is planned to study the hypothesis that;&#xD;
      intracoronary adrenaline is safe and has significantly higher efficacy as compared to&#xD;
      adenosine for the treatment of no-reflow in normotensive patients with acute coronary&#xD;
      syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Thrombolysis in Myocardial Infarction (TIMI) flow grade</measure>
    <time_frame>Immediately after administration of drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in TIMI frame count</measure>
    <time_frame>Immediately after administration of drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The major adverse cardiovascular events</measure>
    <time_frame>During hospital stay and at 30-day follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>No-Reflow Phenomenon</condition>
  <condition>Normotensive</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving intracoronary adrenaline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving intracoronary adenosine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adrenaline</intervention_name>
    <description>Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Control group will receive adenosine (100 to 400 mcg)</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with acute coronary syndrome who developed No-reflow during PCI.&#xD;
&#xD;
          -  Patients with systolic blood pressure of &gt; 100 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypotensive patients&#xD;
&#xD;
          -  Patients with Valvular or congenital heart disease.&#xD;
&#xD;
          -  Patients with Atypical chest pain&#xD;
&#xD;
          -  Patients with Cardiomyopathy&#xD;
&#xD;
          -  Patients with Pericarditis&#xD;
&#xD;
          -  Patients with Myocarditis&#xD;
&#xD;
          -  Patients refused to give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Cardiovascular Diseases</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Cardiovascular Diseases, Karachi</investigator_affiliation>
    <investigator_full_name>Kamran Ahmed Khan</investigator_full_name>
    <investigator_title>Assistant Professor of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>No-Reflow Phenomenon</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

